PBAC passes its first gene therapy
By Megan Brodie 5 years ago | In Cell and gene therapies, Regulatory- 5 years ago
18 October 2021 The PBAC has recommended Novartis’ gene therapy ZOLGENSMA (onasemnogene abeparvovec) for listing…
This is subscriber-only content. Please login to continue reading.